IRIS
MERLINI, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.802
EU - Europa 6.643
AS - Asia 4.699
AF - Africa 22
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 11
SA - Sud America 8
Totale 21.201
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.735
CN - Cina 4.470
IE - Irlanda 2.547
UA - Ucraina 1.054
FI - Finlandia 979
DE - Germania 663
SE - Svezia 441
IT - Italia 413
GB - Regno Unito 246
FR - Francia 116
SG - Singapore 76
CA - Canada 60
BE - Belgio 58
IN - India 53
RU - Federazione Russa 41
JP - Giappone 38
IR - Iran 26
NL - Olanda 19
CZ - Repubblica Ceca 17
MU - Mauritius 16
AT - Austria 13
AU - Australia 12
EU - Europa 10
GR - Grecia 8
TR - Turchia 8
HK - Hong Kong 7
RO - Romania 6
ES - Italia 5
KR - Corea 5
CL - Cile 4
HU - Ungheria 4
NZ - Nuova Zelanda 4
PA - Panama 4
BO - Bolivia 3
MY - Malesia 3
CH - Svizzera 2
DK - Danimarca 2
EE - Estonia 2
IL - Israele 2
LK - Sri Lanka 2
LV - Lettonia 2
MA - Marocco 2
MX - Messico 2
PK - Pakistan 2
RS - Serbia 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BR - Brasile 1
EG - Egitto 1
IQ - Iraq 1
JM - Giamaica 1
KE - Kenya 1
LU - Lussemburgo 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
NP - Nepal 1
PH - Filippine 1
PL - Polonia 1
SA - Arabia Saudita 1
SL - Sierra Leone 1
ZA - Sudafrica 1
Totale 21.201
Salva come PNG Salva come JPEG
Città #
Dublin 2.541
Chandler 2.429
Jacksonville 1.522
Nanjing 1.314
Ashburn 714
Nanchang 563
Princeton 523
Lawrence 489
Wilmington 474
Shenyang 395
Medford 392
Hebei 380
Beijing 365
Changsha 330
Jiaxing 304
Helsinki 297
Ann Arbor 276
Tianjin 222
Hangzhou 212
Boardman 181
Shanghai 140
Woodbridge 111
Milan 101
Norwalk 100
Pavia 96
New York 64
Piscataway 62
Verona 59
Brussels 58
Fairfield 58
Toronto 45
Singapore 44
Des Moines 42
Ningbo 41
Seattle 39
Washington 39
Los Angeles 38
Zhengzhou 35
Chicago 30
Tokyo 30
Pune 27
Jinan 23
Kunming 23
Houston 19
Auburn Hills 17
Taizhou 17
Falls Church 16
Induno Olona 16
Lanzhou 15
Redwood City 15
Orange 14
Brno 12
Guangzhou 12
San Genesio Ed Uniti 12
Tappahannock 12
Falkenstein 11
Fuzhou 11
Dearborn 8
Moscow 8
Zanjan 8
Borås 7
Sydney 7
Andover 6
Berlin 6
Chandigarh 6
Mountain View 6
Rome 6
Tamm 6
Vienna 6
Brescia 5
Hanover 5
Las Vegas 5
Munich 5
Novokuznetsk 5
Rockville 5
San Francisco 5
Bologna 4
Budapest 4
Cambridge 4
London 4
Markham 4
Panama City 4
Phoenix 4
Sacramento 4
Saint Albans 4
St Petersburg 4
Tehran 4
Athens 3
Bari 3
Birmingham 3
Bloomfield 3
Boston 3
Catania 3
Detroit 3
Frankfurt am Main 3
Haikou 3
Hefei 3
Menlo Park 3
Nagold 3
Olomouc 3
Totale 15.625
Salva come PNG Salva come JPEG
Nome #
Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. 103
Valore prognostico della presenza di bassi voltaggi elettrocardiografici nei pazienti affetti da amiloidosi AL 90
Autologous stem cell transplantation following heart transplantation for AL amyloidosis 85
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 82
Fibrillazione atriale e amiloidosi cardiaca AL: un connubio intrigante 81
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils:inhibition of amyloidogenesis. 80
Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. 79
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. 79
Bone marrow amyloidosis. 79
Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis 77
Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. 77
AMYLOIDOSIS AL 76
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 76
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 76
A prospective, controlled, non-randomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple myeloma. 75
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 75
A novel method for proteomic analysis of immunoglobulin light chains and attribution to a germline gene-based family 75
Obstructive intramural coronary amyloidosis: a distinct phenotype of cardiac amyloidosis that can cause acute heart failure. 74
Nutritional status evaluation of patients affected by al amyloidosis: a pilot study 73
International prognostic scoring system for Waldenstrom macroglobulinemia 73
Liver biopsy discloses a new apolipoprotein AI hereditary amyloidosis in several unrelated Italian families 72
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis 72
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 72
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy 72
Acute phase proteins and prognosis in multiple myeloma. 72
Reasoning with Effects of Clinical Guideline Actions Using OWL: AL Amyloidosis as a Case StudyKnowledge Representation for Health-Care 72
Heavy chain disease can be detected by capillary zone electrophoresis. 71
Amino acid sequence of k Sci, the Bence Jones protein isolated from a patient with light chain deposition disease. 70
Utility of biochemicalmarkers in the follow-up of heart transplant recipients 69
Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis 69
AN INTERLEUKIN 2 BINDING FACTOR IN HUMAN SERUM 68
4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. 68
“Separation and quantification of two beta2-microglobulin isoforms”. 67
Waldenstrom's Macroglobulinemia 67
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 67
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 67
Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure. 67
Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide 67
Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. 66
Structural characterization of kappa II Inc, a new amyloid immunoglobulin 66
AL amyloidosis. Characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies 66
Clotting alterations in primary systemic amyloidosis. 65
Early identification of transthyretin-related hereditary cardiac amyloidosis 65
Waldenstrom macroglobulinemia 65
Metodo per la separazione e la quantificazione di due conformazioni di beta-2-microglobulina in equilibrio dinamico 65
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 65
Beta2-microglobulin isoforms display an heterogeneous affinity for type I collagen. 64
Anatomic and Clinical Clues to in vivo mechanisms of amyloidogenesis. in , (2005) vol. 1, pp.29-48. 64
Clonality and specificity of cryoglobulins associated with HCV: pathophysiological implications 64
Amyloid typing: immunoelectron microscopy 64
Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis 64
The red cell distribution width (RDW): value and role in preterm, IUGR (intrauterine growth restricted), full-term infants 64
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 64
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 63
Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome. 63
Determining the significance of MGUS 63
The Pavia approach to clinical protein analysis 63
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 63
Analysis of Vlambda-Jlambda expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambda III) as a new amyloid-associated germline gene segment 63
Comparison of three strategies for myocardial protection during coronary artery bypass graft surgery based on markers of cardiac damage. 62
RELEVANCE OF CLASS, MOLECULAR WEIGHT AND ISOELECTRIC POINT IN PREDICTING HUMAN LIGHT CHAIN AMYLOIDOGENICITY. 62
IMMUNOENZYMATIC DETECTION OF PROTEINS TRANSFERRED ON NITROCELLULOSE AFTER FIXATION AND STAINING IN POLYACRYLAMIDE GEL 62
Use of anti-(beta2 microglobulin) mAb to study formation of amyloid fibrils 62
Proteomics of beta2-microglobulin amyloid fibrils. 62
Pharmacokinetic behavior of Rituximab: a study of different schedules of administration for heterogeneous clinical settings. 62
Characterization of cryoglobulins from patients with type II mixed cryoglobulinaemia associated with HCV 62
Holter monitoring in AL amyloidosis: prognostic implications. 62
Biochemical markers in early diagnosis and management of systemic amyloidoses 62
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 62
IceTrack: a biobank information management system maximizing flexibility and usability 62
STUDY OF THREE PATIENTS WITH MONOCLONAL GAMMAPATHIES AND "LUPUS-LIKE" ANTICOAGULANTS. 61
Topological investigation of amyloid fibrils obtained from beta2-microglobulin 61
Clinical aspects of systemic amyloid diseases. 61
Characterization of the two unique human anti-flavin monoclonal immunoglobulins. 61
A novel approach for the purification and proteomic analysis of pathogenic immunglobulin free light chains from serum 61
Aspectos clinicos del analisis de las proteinas plasmaticas 61
Abnormalities in thrombin-antithrombin pathway in primary systemic amyloidosis. 61
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis 61
Dieta a contenuto controllato di proteine in pazienti affetti da amiloidosi AL con coinvolgimento renale 60
Mutations at position 385 within the hypervariable region 1 (HVR1) of the hepatitis C virus (HCV) are rare and not rescricted to patients with cryoglobulinemia 60
A plea to overcome th concept of "staging" and related inadequacy in multiple myeloma. 60
Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. 60
The controlling roles of Trp60 and Trp95 in beta2-microglobulin function, folding and amyloid aggregation properties. 59
Sjögren’s syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity? 59
Structural features of two monoclonal cryocrystalglobulins causing a rheumatic syndrome with vasculitis. 58
SELECTIVE BONE MARROW INVOLVMENT OF LYMPHOPLASMACYTIC CELLS SECRETING MONOCLONAL IGA RHEUMATOID FACTOR IN A PATIENT WITH SJORGREN'S SYNDROME AND SERUM HYPERVISCOSITY. 58
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. 58
Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. 58
The association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis ineligible for stem cell transplantation 58
A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. 58
Light and electron microscopy immunohistochemical characterization of amyloid deposits 58
Proliferative Activity, Response To Therapy and Survival In Multiple-myeloma 58
AMICA: an electronic patient record specifically designed for an amyloidosis network. 58
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 58
The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44 58
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study 58
Current concepts on the pathogenisis of systemic amyloidosis 57
Guidelines for the analysis of Bence Jones protein. 57
Amyloidosis and Waldenstrom's Macroglobulinemia. 57
A focus on recent advances in proteomics - one step closer to entrance into the clinical arena. 57
Totale 6.635
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.685
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.685
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.179 1.536 2.246 5 201 11 209 59 216 15 421 190 70
2020/20212.289 258 182 61 212 11 277 80 415 128 339 264 62
2021/20222.078 28 13 56 25 42 60 34 144 128 72 317 1.159
2022/20236.994 816 463 81 552 667 736 22 375 2.980 38 157 107
2023/20242.333 290 459 102 200 259 539 41 147 21 63 122 90
2024/2025106 106 0 0 0 0 0 0 0 0 0 0 0
Totale 21.927